Close
CDMO Safety Testing 2026
Novotech

Business & Industry

MHRA Launches Public Consultation on New Rare Disease Therapies Framework to Strengthen UK’s Global Position

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on a proposed Rare Disease Therapies Framework a regulatory proposal that would introduce a new development and authorisation pathway for therapies targeting rare diseases in the...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate NVIDIA's accelerated computing infrastructure and the BioNeMo platform to strengthen AI-driven drug discovery capabilities for pharmaceutical and biotechnology researchers. The collaboration aims to make AI more actionable in research settings...

Decentralized Clinical Trials Market Advances Worldwide

The global Decentralized Clinical Trials Market is expected to grow from USD 9.74 billion in 2025 to USD 34.13 billion by 2035, registering a compound annual growth rate (CAGR) of 13.36% during the forecast period from 2026 to 2035....

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received approval from the U.S. Food and Drug Administration, opening a new treatment pathway for millions of patients whose high blood pressure remains uncontrolled despite existing therapies. The Anglo-Swedish pharmaceutical company...

EU Advances Critical Medicines Act to Cut Import Reliance

The European Union has moved closer to implementing new measures aimed at protecting the availability of essential medicines and reducing exposure to external supply risks, as lawmakers advanced the Critical Medicines Act framework first introduced in March 2025. The...

Agilent, Veeda Lifesciences Launch Biopharma Analytics Hub

Agilent Technologies and Veeda Lifesciences have announced a strategic collaboration aimed at strengthening regulatory-aligned analytical and bioanalytical workflows for biopharma development as GLP-1 and other advanced therapeutic modalities continue to progress across global pipelines. The partnership will combine Agilentโ€™s...

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been signed between Shilpa Medicare Limited and Switzerland-based NXI Therapeutics AG, extending the Indian pharmaceutical companyโ€™s role in global biologics and specialty therapeutics manufacturing. The agreement covers comprehensive chemistry, manufacturing and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป